Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Cafferkey (London, United Kingdom), S. Kostich (London, United Kingdom), P. Jewell (London, United Kingdom), M. Patel (London, United Kingdom), M. Park (London, United Kingdom), T. Harris (London, United Kingdom), G. Canales (London, United Kingdom), G. Russell (London, United Kingdom), O. Kon (London, United Kingdom), L. Martin (London, United Kingdom). TB following targeted and biological therapy: can we predict it?. 487

Member's Comments

No comment yet.

Related content which might interest you: Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019 Can we predict tuberculosis cure? What tools are available? Source: Eur Respir J, 52 (5) 1801089; 10.1183/13993003.01089-2018 Year: 2018 What do new data concerning triple therapy tell us about the risk of infection? Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection Year: 2019 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Can we expect progress from targeted therapy of SCLC? Source: Eur Respir Monogr 2015; 68: 234-246 Year: 2015 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis Source: Eur Respir Monogr 2018; 82: 414-429 Year: 2018 Has the time come to shorten TB treatment and TB preventive therapy? Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Steroids related tuberculosis: Does a subgroup require a more cautious approach? Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011 How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …? Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets? Year: 2019 Is it possible to achieve treatment success, recommended by WHO in country with high level of multidrug resistant TB? Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001 Tuberculosis therapy: past, present and future Source: Eur Respir J 2002; 20: 87S-94S Year: 2002 Can genomic signatures predict response to systemic therapy? Source: Annual Congress 2013 –Biological signatures in thoracic oncology Year: 2013 How quickly do we identify and treat patients with TB ? Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009 TB vaccination: why, when, how and what? Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults Year: 2014 Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021 To be or not to be–could it be drug related pulmonary disease? Source: International Congress 2014 – PG02 Current clinical problems in pulmonology Year: 2014